ONCAlert | Upfront Therapy for mRCC

Updated Results of the MONALEESA-2 Trial in HR+/HER2- Breast Cancer

Sunil Verma, MD
Published Online: 7:52 PM, Tue June 6, 2017

Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses updated results of the phase III MONALEESA-2 trial of first-line ribociclib (Kisqali) plus letrozole (Femara) in hormone receptor-positive, HER2-negative advanced breast cancer during the 2017 ASCO Annual Meeting.

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.